Last reviewed · How we verify
Placebo (for Zonisamide)
Placebo is an inert control substance with no active pharmacological mechanism.
Placebo is an inert control substance with no active pharmacological mechanism. Used for Control arm in Phase 3 clinical trial for Zonisamide.
At a glance
| Generic name | Placebo (for Zonisamide) |
|---|---|
| Sponsor | Boston University Charles River Campus |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a negative control in clinical trials to establish the efficacy of the active drug (Zonisamide) by comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect, allowing researchers to distinguish true drug effects from placebo response and natural disease progression.
Approved indications
- Control arm in Phase 3 clinical trial for Zonisamide
Common side effects
Key clinical trials
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (PHASE3)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study (PHASE2)
- Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism (PHASE3)
- Zonisamide Outpatient Study (PHASE2)
- Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence (PHASE2)
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |